AN2 Therapeutics Accounts Payable

As of the most recent data (March 2026), ANTX shows a accounts payable of $2.6M. That compares with $3.1M in the prior-year period — down 14.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ANTX's accounts payable is now $2.6M (was $3.1M) — a 14.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether AN2 Therapeutics is outperforming or lagging.

Tracking ANTX's accounts payable over time shows whether AN2 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.6M That compares with $3.1M in the prior-year period — down 14.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has AN2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.6M) with ownership activity and broader fundamentals.